PLGA (50:50)
Based on 32 publication(s) in Google Scholar
PLGA (50:50) (poly(lactic-co-glycolic acid) (50:50)) is a copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA) which can be used to fabricate devices for drug delivery and tissue engineering applications.
For research use only. We do not sell to patients.
- Purity: 99.41%
- CAS No.: 34346-01-5
- Formula: (C3H6O3)n.(C2H4O3)n
- Molecular Weight:10000-20000
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) PLGA (50:50)
More- Nat Nanotechnol. 2024 Jun;19(6):834-845. [Abstract]
- Adv Mater. 2024 Mar;36(13):e2312081. [Abstract]
- Nat Protoc. 2025 Apr 10. [Abstract]
- ACS Nano. 2024 Nov 12;18(45):31349-31359. [Abstract]
- J Nanobiotechnology. 2025 Sep 1;23(1):599. [Abstract]
- Adv Sci (Weinh). 2025 Mar;12(10):e2412799. [Abstract]
- Adv Sci (Weinh). 2024 Dec;11(48):e2408044. [Abstract]
- Biomaterials. 2025 Sep:320:123253. [Abstract]
- Chem Eng J. 2026 Apr 1;536:175814.
- Chem Eng J. 2024 Jul 15.
- J Control Release. 2024 Aug 9:374:50-60. [Abstract]
- Small. 2026 Feb 7:e12379. [Abstract]
- Adv Healthc Mater. 2025 Sep 30:e01619. [Abstract]
- Int J Nanomedicine. 2024 Apr 17:19:3589-3605. [Abstract]
- Mol Ther Oncolytics. 2021 Nov 29:24:1-13. [Abstract]
- Biofabrication. 2022 Oct 27;15(1). [Abstract]
- Cell Prolif. 2021 Aug;54(8):e13089. [Abstract]
- Cell Prolif. 2021 Jan;54(1):e12954. [Abstract]
- Anal Chem. 2026 May 26;98(20):15053-15065. [Abstract]
- ACS Appl Nano Mater. 2025 Apr 23.
- Commun Biol. 2023 Feb 16;6(1):184. [Abstract]
- AAPS PharmSciTech. 2024 May 30;25(5):120. [Abstract]
- Eur J Pharm Biopharm. 2026 Jul:224:115081. [Abstract]
- J Mol Struct. 2026 Jan 8;1357:145297.
- Mol Pharm. 2025 Aug 4;22(8):4794-4803. [Abstract]
- Mol Pharm. 2021 Jul 5;18(7):2495-2506. [Abstract]
- J Photochem Photobiol B. 2024 Sep:258:112999. [Abstract]
- Biomed Mater. 2024 Aug 22;19(5). [Abstract]
- Eur Cell Mater. 2025.
- University of Osaka. 2025.
- Food biomacromolecules. 2025 Jun 20.
- Biomed Pharmacother. 2020 Sep:129:110371. [Abstract]
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
WB
-
IF
-
WB
Biological Activity
PLGA (50:50) can be used to prepare nanoparticles with different surface properties for biological experiments[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 34346-01-5
-
Appearance Solid
-
Molecular Weight 10000-20000
-
Formula (C3H6O3)n.(C2H4O3)n
-
Color White to off-white
-
SMILES
O=C(O)C(C)OC(CO[H])=O.[x].[y]
-
Synonyms
poly(lactic-co-glycolic acid) (50:50)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (32)
-
Journal Impact Factor
-
Most Recent
-
Nat Nanotechnol
Photothermal therapy of tuberculosis using targeting pre-activated macrophage membrane-coated nanoparticles. [Abstract]2024 Jun;19(6):834-845. PMID: 38383890 -
Adv Mater
Magnetic Aggregation-Induced Bone-Targeting Nanocarrier with Effects of Piezo1 Activation and Osteogenic-Angiogenic Coupling for Osteoporotic Bone Repair. [Abstract]2024 Mar;36(13):e2312081. PMID: 38102981 -
Nat Protoc
NIR-II aggregation-induced emission nanoparticles camouflaged with preactivated macrophage membranes for phototheranostics of pulmonary tuberculosis. [Abstract]2025 Apr 10. PMID: 40210746 -
ACS Nano
2024 Nov 12;18(45):31349-31359. PMID: 39485232 -
J Nanobiotechnology
Intraoperative application of an antioxidant nanoparticle-hydrogel targeting microglia regulates neuroinflammation in traumatic brain injury. [Abstract]2025 Sep 1;23(1):599. PMID: 40890874 -
Adv Sci (Weinh)
Intestine-Decipher Engineered Capsules Protect Against Sepsis-induced Intestinal Injury via Broad-spectrum Anti-inflammation and Parthanatos Inhibition. [Abstract]2025 Mar;12(10):e2412799. PMID: 39836501
PLGA (50:50) purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(10):e2412799. [Abstract]
Hydrodynamic sizes of PLGA (10 mg/mL; 4 h) cores, MΦ NPs, OLA@MΦ NPs, and OLA@MΦ NPs-2 (OLA@MΦ NPs isolated from cp-OLA@MΦ NPs) were measured (n = 3).
PLGA (50:50) purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(10):e2412799. [Abstract]
PLGA (10 mg/mL; 4 h). TEM images of PLGA cores and OLA@MΦ NPs-2 were obtained.
PLGA (50:50) purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(10):e2412799. [Abstract]
PLGA (10 mg/mL; 4 h). Western blot analysis of IL-1R, IL-6R, TNFR, and TLR4 in PLGA cores, MΦ NPs, OLA@MΦ NPs, and OLA@MΦ NPs-2.
-
Adv Sci (Weinh)
Concrete-Inspired Bionic Bone Glue Repairs Osteoporotic Bone Defects by Gluing and Remodeling Aging Macrophages. [Abstract]2024 Dec;11(48):e2408044. PMID: 39455287 -
Biomaterials
Phase-adapted metal ion supply for spinal cord repair with a Mg-Zn incorporated chimeric microsphere. [Abstract]2025 Sep:320:123253. PMID: 40107180 -
-
-
J Control Release
2024 Aug 9:374:50-60. PMID: 39111599 -
Small
Biocompatible Glue-Enabled Drug Localization and Mechanical Reinforcement of Lyophilized Microneedle Systems. [Abstract]2026 Feb 7:e12379. PMID: 41653461 -
Adv Healthc Mater
Trans-Organ Early Intervention for Myocardial Infarction Based on Bone Marrow-Homing Biomimetic Nanomedicine. [Abstract]2025 Sep 30:e01619. PMID: 41025748 -
Int J Nanomedicine
Regulating Tumor-Associated Macrophage Polarization by Cyclodextrin-Modified PLGA Nanoparticles Loaded with R848 for Treating Colon Cancer. [Abstract]2024 Apr 17:19:3589-3605. PMID: 38645464 -
Mol Ther Oncolytics
Dual-targeting vaccine of FGL1/CAIX exhibits potent anti-tumor activity by activating DC-mediated multi-functional CD8 T cell immunity. [Abstract]2021 Nov 29:24:1-13. PMID: 34977338 -
Biofabrication
Development of non-adherent cell-enclosing domes with enzymatically cross-linked hydrogel shell. [Abstract]2022 Oct 27;15(1). PMID: 36170845 -
Cell Prolif
Thymopentin alleviates premature ovarian failure in mice by activating YY2/Lin28A and inhibiting the expression of let-7 family microRNAs. [Abstract]2021 Aug;54(8):e13089. PMID: 34180104 -
Cell Prolif
MicroRNA-146b-5p overexpression attenuates premature ovarian failure in mice by inhibiting the Dab2ip/Ask1/p38-Mapk pathway and γH2A.X phosphorylation. [Abstract]2021 Jan;54(1):e12954. PMID: 33166004 -
Anal Chem
2026 May 26;98(20):15053-15065. PMID: 42102103 -
-
Commun Biol
Nanodrug rescues liver fibrosis via synergistic therapy with H2O2 depletion and Saikosaponin b1 sustained release. [Abstract]2023 Feb 16;6(1):184. PMID: 36797395 -
AAPS PharmSciTech
Development, Characterization and In Vitro Gastrointestinal Release of PLGA Nanoparticles Loaded with Full-Spectrum Cannabis Extracts. [Abstract]2024 May 30;25(5):120. PMID: 38816596 -
Eur J Pharm Biopharm
Spatiotemporally controlled systemic delivery reshapes the in vivo fate of a cationic antimicrobial peptide for lung-selective exposure and an improved therapeutic index. [Abstract]2026 Jul:224:115081. PMID: 42044857 -
-
Mol Pharm
Intravenous Administration of Antisense Oligonucleotide Incorporated into PLGA Nanoparticles Alters the Pattern of Organ Distribution and Gene Knockdown Effects. [Abstract]2025 Aug 4;22(8):4794-4803. PMID: 40682830 -
Mol Pharm
Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy. [Abstract]2021 Jul 5;18(7):2495-2506. PMID: 34078087 -
J Photochem Photobiol B
Carrier cascade target delivery of 5-aminolevulinic acid nanoplatform to enhance antitumor efficiency of photodynamic therapy against lung cancer. [Abstract]2024 Sep:258:112999. PMID: 39126752 -
Biomed Mater
Ti3C2T x@PLGA/Icaritin microspheres-modified PLGA/ β-TCP scaffolds modulate Icaritin release to enhance bone regeneration through near-infrared response. [Abstract]2024 Aug 22;19(5). PMID: 39121886 -
-
-
-
Biomed Pharmacother
Biomimetic nanoparticle loading obatoclax mesylate for the treatment of non-small-cell lung cancer (NSCLC) through suppressing Bcl-2 signaling. [Abstract]2020 Sep:129:110371. PMID: 32563984
PLGA (50:50) purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Sep:129:110371. [Abstract]
Immunofluorescence staining displays weaker Bcl-2 fluorescence intensity in lung cancer cells incubated with RBCm-Obatoclax Mesylate (OM)/PLGA, accompanied with stronger expression of pro-apoptotic signal Bax in comparison to the Con group.
PLGA (50:50) purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Sep:129:110371. [Abstract]
Bcl-2 and Bcl-xl protein expression levels are restrained in A549 and H1975 cells treated with RBCm-OM/PLGA; however, Bax, cleaved Caspase-3, Caspase-9 and PARP are up-regulated following RBCm-OM/PLGA incubation. Also, free Obatoclax Mesylate (OM) does not influence the expression change of all these proteins.
Solvent & Solubility
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Makadia HK, et al. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel). 2011 Sep 1;3(3):1377-1397. [Content Brief]
[2]. Chung TW, Tsai YL, Hsieh JH, Tsai WJ. Different ratios of lactide and glycolide in PLGA affect the surface property and protein delivery characteristics of the PLGA microspheres with hydrophobic additives. J Microencapsul. 2006;23(1):15-27. [Content Brief]
[3]. Mura S, et al. Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int J Nanomedicine. 2011;6:2591-605. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)